Sensible Biotechnologies secured $47.0M in funding, announced in Oxford, England, to advance its naturally modified mRNA platform and develop next-generation mRNA medicines. Based on the provided article excerpt, the round designation (e.g., first round vs. follow-on), key investors, and valuation were not disclosed, nor were specific metrics such as revenue, client count, pipeline candidates, or employee count. Beyond advancing the platform, detailed planned use of funds or expansion plans were not specified in the excerpt.